drugset / Trial / NCT01947803

A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia

NCT01947803

Phase 4 Completed 353 enrolled Xian-Janssen Pharmaceutical Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study will be to evaluate the safety and treatment response of paliperidone palmitate administered to Chinese patients with schizophrenia.

Timeline

Start
2013-09
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject paliperidone palmitate Unknown 75 mg Intramuscular
Subject paliperidone palmitate Unknown 150 mg Intramuscular

Indications